136 related articles for article (PubMed ID: 20332141)
1. Lymphocyte-predominant Hodgkin lymphoma--clinical features and treatment outcomes from a 30-year experience.
Jackson C; Sirohi B; Cunningham D; Horwich A; Thomas K; Wotherspoon A
Ann Oncol; 2010 Oct; 21(10):2061-2068. PubMed ID: 20332141
[TBL] [Abstract][Full Text] [Related]
2. Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era.
King MT; Donaldson SS; Link MP; Natkunam Y; Advani RH; Hoppe RT
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):67-75. PubMed ID: 25863755
[TBL] [Abstract][Full Text] [Related]
3. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.
Diehl V; Sextro M; Franklin J; Hansmann ML; Harris N; Jaffe E; Poppema S; Harris M; Franssila K; van Krieken J; Marafioti T; Anagnostopoulos I; Stein H
J Clin Oncol; 1999 Mar; 17(3):776-83. PubMed ID: 10071266
[TBL] [Abstract][Full Text] [Related]
4. Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation.
Calvo-Villas JM; Martín A; Conde E; Pascual A; Heras I; Varela R; de la Rubia J; Ramirez MJ; Díez-Martín JL; Panizo C; Rodríguez-Salazar MJ; Pascual MJ; Donato EM; González-Barca E; Caballero MD;
Ann Oncol; 2010 Sep; 21(9):1891-1897. PubMed ID: 20231299
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in lymphocyte-predominant Hodgkin disease.
Azim HA; Pruneri G; Cocorocchio E; Cinieri S; Raviele PR; Bassi S; Preda L; Martinelli G; Peccatori FA
Oncology; 2009; 76(1):26-9. PubMed ID: 19033694
[TBL] [Abstract][Full Text] [Related]
6. The German Hodgkin Study Group risk model is useful for Hodgkin lymphoma patients receiving radiotherapy after autologous stem cell transplant.
Furlan C; Matrone F; Rupolo M; Ciancia R; Zanet E; Montante B; Palazzari E; Navarria F; Trovo M; Bulian P; Spina M; Coassin E; Mascarin M; De Paoli A; Franchin G; Michieli M
Cancer Radiother; 2019 Sep; 23(5):378-384. PubMed ID: 31178272
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
[TBL] [Abstract][Full Text] [Related]
8. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial.
Ekstrand BC; Lucas JB; Horwitz SM; Fan Z; Breslin S; Hoppe RT; Natkunam Y; Bartlett NL; Horning SJ
Blood; 2003 Jun; 101(11):4285-9. PubMed ID: 12586628
[TBL] [Abstract][Full Text] [Related]
9. Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease.
Bodis S; Kraus MD; Pinkus G; Silver B; Kadin ME; Canellos GP; Shulman LN; Tarbell NJ; Mauch PM
J Clin Oncol; 1997 Sep; 15(9):3060-6. PubMed ID: 9294468
[TBL] [Abstract][Full Text] [Related]
10. Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
Hertzberg MS; Crombie C; Benson W; Taper J; Gottlieb D; Bradstock KF
Ann Oncol; 2006 May; 17 Suppl 4():iv25-30. PubMed ID: 16702181
[TBL] [Abstract][Full Text] [Related]
11. Contribution of involved-field radiotherapy to survival in patients with relapsed or refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
Eroglu C; Kaynar L; Orhan O; Keklik M; Sahin C; Yildiz OG; Mentes S; Kurnaz F; Aslan D; Sivgin S; Soyuer S; Eser B; Cetin M; Unal A
Am J Clin Oncol; 2015 Feb; 38(1):68-73. PubMed ID: 23563207
[TBL] [Abstract][Full Text] [Related]
12. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group.
Biasoli I; Stamatoullas A; Meignin V; Delmer A; Reman O; Morschhauser F; Coiffier B; Bosly A; Diviné M; Brice P
Cancer; 2010 Feb; 116(3):631-9. PubMed ID: 20029973
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
14. European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease.
Wilder RB; Schlembach PJ; Jones D; Chronowski GM; Ha CS; Younes A; Hagemeister FB; Barista I; Cabanillas F; Cox JD
Cancer; 2002 Mar; 94(6):1731-8. PubMed ID: 11920535
[TBL] [Abstract][Full Text] [Related]
15. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience.
Viviani S; Di Nicola M; Bonfante V; Di Stasi A; Carlo-Stella C; Matteucci P; Magni M; Devizzi L; Valagussa P; Gianni AM
Leuk Lymphoma; 2010 Jul; 51(7):1251-9. PubMed ID: 20528244
[TBL] [Abstract][Full Text] [Related]
17. Clinical presentation and outcomes of lymphocyte-predominant Hodgkin disease at the University of Florida.
Chera BS; Olivier K; Morris CG; Lynch JW; Mendenhall NP
Am J Clin Oncol; 2007 Dec; 30(6):601-6. PubMed ID: 18091054
[TBL] [Abstract][Full Text] [Related]
18. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
19. Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year follow-up in the West of Scotland Cancer Network.
Farrell K; McKay P; Leach M
Leuk Lymphoma; 2011 Oct; 52(10):1920-8. PubMed ID: 21663507
[TBL] [Abstract][Full Text] [Related]
20. Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma: a report of 21 cases from the Nebraska Lymphoma Study Group.
Huang JZ; Weisenburger DD; Vose JM; Greiner TC; Aoun P; Chan WC; Lynch JC; Bierman PJ; Armitage JO
Leuk Lymphoma; 2004 Aug; 45(8):1551-7. PubMed ID: 15370206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
